Results 221 to 230 of about 285,048 (302)
ABSTRACT Background Although shifts in nasal microbiota have been well‐documented in inflammatory upper airway conditions, microbiota tumor‐associated alterations remain uncharacterized. This study is the first to compare sinonasal microbiota profiles of patients with malignant tumors (MT), benign tumors (BT), and controls, offering insights into tumor‐
Evan A. Patel +13 more
wiley +1 more source
Impact of Primary Health Care Data Quality on Infectious Disease Surveillance in Brazil: Case Study. [PDF]
Florentino PTV +10 more
europepmc +1 more source
ABSTRACT Background Bitter taste receptors (T2Rs) function in the innate immune defense of the sinonasal mucosa; however, the genetic association between the TAS2R gene family and chronic rhinosinusitis (CRS) remains understudied in Asian populations.
Rong‐San Jiang +6 more
wiley +1 more source
Salmonella surveillance annual summary 1979
Issued November 1981SUMMARY: In 1979, 31,123 isolations of Salmonella from humans were reported to the Centers for Disease Control, an increase of 2,375 isolations (8.3%) over 1978, and the greatest number of isolations reported to the Centers in any ...
core
Integrating testing volume into bandit algorithms for infectious disease surveillance. [PDF]
Warren JL +4 more
europepmc +1 more source
Development of a wastewater based infectious disease surveillance research system in South Korea. [PDF]
Kim YT +12 more
europepmc +1 more source
ABSTRACT Background Chronic rhinosinusitis (CRS) represents a spectrum of inflammatory endotypes, driven by distinct T helper (Th) immune responses. The high rate of recurrent disease despite appropriate medical and surgical interventions highlights the need for improved characterization beyond the traditional type 2 and non‐type 2 phenotypes to better
Liyona Kampel +9 more
wiley +1 more source
Editorial: Application of spatial information technology in infectious disease surveillance. [PDF]
Xu M, Cao C, Li Z, Zhao L.
europepmc +1 more source
In multiple sclerosis (MS), anti‐CD20 therapies have been associated with increased infection risk, but whether this risk differs between rituximab and ocrelizumab is not known. Using a nationwide cohort, we studied infection risk and relapse outcomes among 16,872 treatment episodes with rituximab, ocrelizumab, or other disease‐modifying therapies ...
Thomas Frisell +2 more
wiley +1 more source

